|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.66 CNY | +0.89% |
|
+0.18% | -24.63% |
| 05-07 | Shuangcheng Pharma Gets FDA Nod to Market Acromegaly Drug in US | MT |
| 04-29 | Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Hainan Shuangcheng Pharmaceuticals Co., Ltd. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was CNY 320.29 million compared to CNY 269.44 million a year ago. Net loss was CNY 20.33 million compared to CNY 53.33 million a year ago.
Basic loss per share from continuing operations was CNY 0.05.
| 1st Jan change | Capi. | |
|---|---|---|
| -24.63% | 324M | |
| +21.63% | 44.12B | |
| +22.99% | 22.71B | |
| +18.22% | 15.15B | |
| +12.66% | 13.61B | |
| +60.18% | 13.34B | |
| -8.35% | 6.84B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.92% | 5.63B |
HAINAN SHUANGCHENG PHARMACEUTICALS CO., LTD. 
